← All trials
NCT04385966
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 11, 2020
- Primary completion
- Jan 15, 2021
- Completion date
- Jan 15, 2021
- First posted
- May 13, 2020
- Last posted
- May 13, 2020
- Enrollment
- 48
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Instituto de Investigación Sanitaria AragónLead sponsor
- University of ZaragozaCollaborator
- University of ZaragozaOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.